|
|
|||||||||
CA: A Cancer Journal for Clinicians, Vol 48, Issue 4 199-209, Copyright © 1998 by American Cancer Society
B. Vikram
Many challenges remain, but considerable progress has been made in this
field since 1983, when we published in this journal an article titled
"Adjuvant Radiation Therapy in Locally Advanced Head and Neck Cancer."
Several clinical and pathologic features have been identified that can
stratify patients according to the risk of relapse (whether at the primary
site, in the neck, or at distant sites) or the risk of second cancers, so
that additional adjuvant treatment might be administered only to patients
who are the most likely to benefit from it. Hope exists that in the near
future our capabilities will be bolstered by the availability of powerful
new biologic and molecular genetic tools. The greatest advance, perhaps,
has been the recognition that adjuvant therapy for head and neck cancer
should not be an afterthought but part of a thoughtfully crafted
interdisciplinary strategy aimed at maximizing tumor control with the least
morbidity.
ARTICLES
Adjuvant therapy in head and neck cancer
Unified Department of Radiation Oncology, Albert Einstein College of Medicine, Bronx, NY, USA.
This article has been cited by other articles:
![]() |
Q. Sun, T. Sakaida, W. Yue, S. M. Gollin, and J. Yu Chemosensitization of head and neck cancer cells by PUMA Mol. Cancer Ther., December 1, 2007; 6(12): 3180 - 3188. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | COVER ARCHIVE | SEARCH | TABLE OF CONTENTS |